
Please try another search
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours. It also develops GB226, which is in Phase III clinical trial; GB261, which is in Phase I/II clinical trial for NHL; and GB263T that is in Phase I/II clinical trial for NSCLC. In addition, the company develops GB221, which is in Phase III clinical trial for HER2+ 1L/2L+ mBC; GB223 that is in Phase I clinical trial for GCTB, PMO; GB241 that is in Phase III clinical trial for 1L DLBCL; and GB251, which is in Phase I clinical trial for HER2+ 1L/2L+ mBC. Further, the company’s product candidates that are in pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for cancer treatment. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Zhijian Chen | - | 2021 | Chairman of Scientific Advisory Board |
John F. Seymour | - | 2021 | Member of Scientific Advisory Board |
Alex A. Adjei | 69 | 2021 | Member of Scientific Advisory Board |
Dong Lyu | 49 | 2021 | Non Executive Director |
David J. Kerr | - | 2021 | Member of Scientific Advisory Board |
Chengyi Weng | 44 | 2024 | CFO & Executive Director |
Wen Chen | 57 | 2020 | Independent Non-Executive Director |
Yangxin Fu | - | 2021 | Member of Scientific Advisory Board |
Yi Liu | 35 | 2022 | Non-Executive Director |
Edwin Fung | 60 | 2020 | Independent Non-Executive Director |
Leonard B. Saltz | - | 2021 | Member of Scientific Advisory Board |
Tieming Yu | 43 | 2024 | Non-Executive Director |
John R. Zalcberg | - | 2021 | Member of Scientific Advisory Board |
Bai Cui | 43 | 2024 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review